CLINICAL_TRIALS
trial_result
· 2019-03-14
Clinical Trial Update: A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors [Phase 1]
Summary
Phase 1 trial of MLN8237 (Aurora A kinase inhibitor) in participants with advanced solid tumors completed; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Advanced Malignancies | Phase 1 | Status: COMPLETED | Results posted: 2019-03-14